Expand BBH Menu
BBH MENU

BBH ETF Profile


Family: Van Eck Associates Corporation
Name: VanEck Biotech ETF
Inception Date: 20-Dec-2011
Termination Date:
Investment Objective: VanEck Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.
Prospectus
Top 10 Holdings
Amgen Inc AMGN 15.0200%
Vertex Pharmaceuticals Inc VRTX 9.5200%
Gilead Sciences Inc GILD 7.8000%
Regeneron Pharmaceuticals Inc REGN 7.7000%
Moderna Inc MRNA 5.7800%
Iqvia Holdings Inc IQV 4.9600%
Argenx Se ARGX 4.4400%
Biogen Inc BIIB 4.3600%
Icon Plc ICLR 4.3300%
Illumina Inc ILMN 4.2200%
Top 10 Holdings Weight: 68.1%
Number of Holdings: 27
Shares Outstanding: 2,696,503
Total Net Assets: 424,240,800
NAV: 157.49
Net Expense Ratio: 0.35%
Asset Class: Equities (Stocks)
Developed or Emerging: Developed Market Funds
Country:
Region:
Strategy:
Currency:
Commodity:
Sector: Healthcare
Industry: Biotech
Dividend Type:
Tax Exempt State:
Maturity Duration:
Market Cap: Broad Market / Multi-Cap
Credit Quality:
Mortgage Bond Types:
Bond Type:
Gov't Bond Types:
Reit Type:
Leverage Direction/Factor:
Is Currency Hedged: No
US or Ex-US: Global